Analyst Insights: Sanderson, Par Pharmaceutical May 30th

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Sanderson Farms, Inc. (NASDAQ:SAFM): Goldman recommends aggressively buying Sanderson Farms following weakness related to concerns regarding breast and leg quarter prices. The firm raised its FY12 EPS estimate above the Street given faster than expected profit improvement. Shares are Conviction Buy rated with a $65 price target.

Par Pharmaceutical Companies Inc. (NYSE:PRX): Needham said the ruling against Par Pharmaceutical in its patent fight for generic Lovaza could continue to weigh on shares, though the firm does not believe it significantly diminishes the chances of Par achieving its 2012-2014 EPS guidance. Needham sees generic Lovaza as off the table for at least the next 12-18 months but still thinks the risk/reward on Par shares is favorable and maintains a Strong Buy rating on the stock.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business